GSK chief rules out AstraZeneca buyout

GSK ($GSK) chief Andrew Witty (photo) quickly dismissed any idle speculation that he might be interested in buying the struggling British rival AstraZeneca ($AZN). A buyout, he said, would be "very distracting". Some analysts have been wondering if David Brennan's departure at Astra would set the stage for a big merger. But such megadeals are in distinct disfavor right now. Story

 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.